Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 20, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Divalproex Sodium Delayed-Release Capsules USP, 125 mg.".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 20, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Divalproex Sodium Delayed-Release Capsules USP, 125 mg.".